H.C. Wainwright raised the firm’s price target on MoonLake Immunotherapeutics (MLTX) to $40 from $32 and keeps a Buy rating on the shares. The firm says the “favorable” axial spondyloarthritis data augments MoonLake’s existing clinical data and opens up a new market opportunity.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MLTX:
- MoonLake Immunotherapeutics price target raised to $11 from $10 at Goldman Sachs
- MoonLake Immunotherapeutics price target raised to $35 from $30 at Oppenheimer
- Sonelokimab: Strong HS and AxSpA Data, Clear Regulatory Path Support Best‑in‑Class Potential and Buy Rating
- MoonLake Highlights Positive S-OLARIS Data and Investor Day
- MoonLake announces results from Phase 2 trial of Sonelokimab